Cargando…

Exposure‐toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer

Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has been observed in renal cell carcinoma patients (RCC) with a cabozantinib exposure greater than 750 μg/L. In our study we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krens, Stefanie D., van Boxtel, Wim, Uijen, Maike J. M., Jansman, Frank G. A., Desar, Ingrid M. E., Mulder, Sasja F., van Herpen, Carla M. L., van Erp, Nielka P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291492/ https://www.ncbi.nlm.nih.gov/pubmed/34494665 http://dx.doi.org/10.1002/ijc.33797

Ejemplares similares

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands
por: Valstar, Matthijs H., et al.
Publicado: (2020)

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour
por: Westerdijk, Kim, et al.
Publicado: (2020)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

The potential of breast cancer screening in Europe
por: Zielonke, Nadine, et al.
Publicado: (2020)

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Identifying key factors for the effectiveness of pancreatic cancer screening: A model‐based analysis
por: Koopmann, Brechtje D. M., et al.
Publicado: (2021)

Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple‐negative breast cancer
por: Heeg, Erik, et al.
Publicado: (2019)

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
por: Hermus, Merel, et al.
Publicado: (2022)

The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut‐off level on yield of screening
por: Kooyker, Arthur I., et al.
Publicado: (2020)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Effect of screening mammography on breast cancer mortality: Quasi‐experimental evidence from rollout of the Dutch population‐based program with 17‐year follow‐up of a cohort
por: Van Ourti, Tom, et al.
Publicado: (2019)

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
por: Bouwer, Nathalie I., et al.
Publicado: (2022)

Reliable identification of women with CIN3+ using hrHPV genotyping and methylation markers in a cytology‐screened referral population
por: Leeman, Annemiek, et al.
Publicado: (2018)

Discontinuation of anti‐PD‐1 monotherapy in advanced melanoma—Outcomes of daily clinical practice
por: van Zeijl, Michiel C. T., et al.
Publicado: (2021)

The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2− advanced breast cancer patients: A study of the Dutch SONABRE Registry
por: Meegdes, Marissa, et al.
Publicado: (2021)

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019)

The unfavorable effects of COVID‐19 on Dutch advanced melanoma care
por: van Not, Olivier J., et al.
Publicado: (2021)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Human papillomavirus‐based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial
por: Gottschlich, Anna, et al.
Publicado: (2022)

Finding the optimal mammography screening strategy: A cost‐effectiveness analysis of 920 modelled strategies
por: Kregting, Lindy M., et al.
Publicado: (2022)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Acute aerobic exercise‐conditioned serum reduces colon cancer cell proliferation in vitro through interleukin‐6‐induced regulation of DNA damage
por: Orange, Samuel T., et al.
Publicado: (2022)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Cervical cancer risk in HPV‐positive women after a negative FAM19A4/mir124‐2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow‐up
por: De Strooper, Lise M.A., et al.
Publicado: (2018)

Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo
por: Voloshin, Tali, et al.
Publicado: (2016)

Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort
por: Li, Jingmei, et al.
Publicado: (2018)

COVID‐19 and access to cancer care in Kenya: patient perspective
por: Umar, Shahid, et al.
Publicado: (2022)

Global colorectal cancer research, 2007‐2021: Outputs and funding
por: Begum, Mursheda, et al.
Publicado: (2022)

Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries
por: Henson, Katherine E., et al.
Publicado: (2020)

Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance
por: Basu, Partha, et al.
Publicado: (2018)

Lectin‐based phototherapy targeting cell surface glycans for pancreatic cancer
por: Kuroda, Yukihito, et al.
Publicado: (2022)

The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk
por: MacKintosh, Michelle L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_34eelf5lmq74ukhbcrlb0uuiv9